Vers une réduction du risque de rechute des patientes présentant un cancer du sein localisé surexprimant HER2 ?

摘要

The treatment of HER2-overexpressing localized breast cancer is undergoing significant transformation. While trastuzumab has significantly improved the prognosis for these patients, almost 30% will have a relapse within 11 years. With such a high recurrence rate, optimization of HER2 pathway inhibition at an early stage is mandatory. HER2-targeted therapies with a favourable impact at the metastatic stage have been evaluated in Phase II and III trials, and have demonstrated superiority regarding complete response rate or disease-free survival, compared to a treatment with trastuzumab alone.